Selection against PUMA Gene Expression in Myc-Driven B-Cell Lymphomagenesis

REFERENCES

• Adams, J. M., A. W. Harris, C. A. Pinkert, L. M. Corcoran, W. S. Alexander, S. Cory, R. D. Palmiter, and R. L. Brinster. 1985. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318:533–538.
   PubMed Web of Science ®Google Scholar
• Alt, J. R., T. C. Greiner, J. L. Cleveland, and C. M. Eischen. 2003. Mdm2 haploinsufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBO J. 22:1442–1450.
   PubMedGoogle Scholar
• Boxer, L. M., and C. V. Dang. 2001. Translocations involving c-myc and c-myc function. Oncogene 20:5595–5610.
   PubMed Web of Science ®Google Scholar
• Cadwell, C., and G. P. Zambetti. 2001. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 277:15–30.
   PubMed Web of Science ®Google Scholar
• Chau, C. M., X. Y. Zhang, S. B. McMahon, and P. M. Lieberman. 2006. Regulation of Epstein-Barr virus latency type by the chromatin boundary factor CTCF. J. Virol. 80:5723–5732.
   PubMedGoogle Scholar
• Christman, J. K. 2002. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21:5483–5495.
   PubMed Web of Science ®Google Scholar
• Curradi, M., A. Izzo, G. Badaracco, and N. Landsberger. 2002. Molecular mechanisms of gene silencing mediated by DNA methylation. Mol. Cell. Biol. 22:3157–3173.
   PubMed Web of Science ®Google Scholar
• Douglas, D. B., Y. Akiyama, H. Carraway, S. A. Belinsky, M. Esteller, E. Gabrielson, S. Weitzman, T. Williams, J. G. Herman, and S. B. Baylin. 2004. Hypermethylation of a small CpGuanine-rich region correlates with loss of activator protein-2α expression during progression of breast cancer. Cancer Res. 64:1611–1620.
   PubMed Web of Science ®Google Scholar
• Doumont, G., A. Martoriati, C. Beekman, S. Bogaerts, P. J. Mee, F. Bureau, E. Colombo, M. Alcalay, E. Bellefroid, F. Marchesi, E. Scanziani, P. G. Pelicci, and J.-C. Marine. 2005. G1 checkpoint failure and increased tumor susceptibility in mice lacking the novel p53 target Ptprv. EMBO J. 24:3093–3103.
   PubMedGoogle Scholar
• Egle, A., A. W. Harris, P. Bouillet, and S. Cory. 2004. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc. Natl. Acad. Sci. USA 101:6164–6169.
   PubMed Web of Science ®Google Scholar
• Eischen, C. M., M. F. Roussel, S. J. Korsmeyer, and J. L. Cleveland. 2001. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol. Cell. Biol. 21:7653–7662.
   PubMed Web of Science ®Google Scholar
• Eischen, C. M., J. D. Weber, M. F. Roussel, C. J. Sherr, and J. L. Cleveland. 1999. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 13:2658–2669.
   PubMed Web of Science ®Google Scholar
• Eischen, C. M., D. Woo, M. F. Roussel, and J. L. Cleveland. 2001. Apoptosis triggered by Myc-induced suppression of Bcl-XL or Bcl-2 is bypassed during lymphomagenesis. Mol. Cell. Biol. 21:5063–5070.
   PubMed Web of Science ®Google Scholar
• el-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817–825.
   PubMed Web of Science ®Google Scholar
• Erlacher, M., V. Labi, C. Manzl, G. Böck, A. Tzankov, G. Häcker, E. Michalak, A. Strasser, and A. Villunger. 2006. Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction. J. Exp. Med. 203:2939–2951.
   PubMed Web of Science ®Google Scholar
• Finch, A., J. Prescott, K. Shchors, A. Hunt, L. Soucek, T. B. Dansen, L. B. Swigart, and G. I. Evan. 2006. Bcl-xL gain of function and p19 ARF loss of function cooperate oncogenically with Myc in vivo by distinct mechanisms. Cancer Cell 10:113–120.
   PubMed Web of Science ®Google Scholar
• Hajkova, P., O. El-Maarri, S. Engemann, J. Oswald, A. Olek, and J. Walter. 2002. DNA-methylation analysis by the bisulfite-assisted genomic sequencing method, p. 143-154. In K. I. Mills and B. H. Ramsahoye (ed.), DNA methylation protocols. Human Press, Totowa, NJ.
   Google Scholar
• Han, J., C. Flemington, A. B. Houghton, Z. Gu, G. P. Zambetti, R. J. Lutz, L. Zhu, and T. Chittenden. 2001. Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals. Proc. Natl. Acad. Sci. USA 98:11318–11323.
   PubMed Web of Science ®Google Scholar
• Hemann, M. T., J. S. Fridman, J. T. Zilfou, E. Hernando, P. J. Paddison, C. Cordon-Cardo, G. J. Hannon, and S. W. Lowe. 2003. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat. Genet. 33:396–400.
   PubMed Web of Science ®Google Scholar
• Hemann, M. T., J. T. Zilfou, Z. Zhao, D. J. Burgess, G. J. Hannon, and S. W. Lowe. 2004. Suppression of tumorigenesis by the p53 target PUMA. Proc. Natl. Acad. Sci. USA 101:9333–9338.
   PubMedGoogle Scholar
• Hemann, M. T., A. Bric, A. Herbst, J. Felstein, C. Cordon-Cardo, J. L. Cleveland, W. P. Tansey, and S. W. Lowe. 2005. Evasion of the p53 tumor surveillance network by tumor-derived myc mutants. Nature 436:807–811.
   PubMed Web of Science ®Google Scholar
• Hsieh, C.-L. 1997. Stability of patch methylation and its impact in regions of transcriptional initiation and elongation. Mol. Cell. Biol. 17:5897–5904.
   PubMed Web of Science ®Google Scholar
• Hsu, B., M. C. Marin, A. K. el-Naggar, L. C. Stephens, S. Brisbay, and T. J. McDonnell. 1995. Evidence that c-myc mediated apoptosis does not require wild-type p53 during lymphomagenesis. Oncogene 11:175–179.
   PubMedGoogle Scholar
• Issa, J. P., G. Garcia-Manero, F. J. Giles, R. Mannari, D. Thomas, S. Faderl, E. Bayar, J. Lyons, C. S. Rosenfeld, J. Cortes, and H. M. Kantarjian. 2004. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103:1635–1640.
   PubMed Web of Science ®Google Scholar
• Jeffers, J. R., E. Parganas, Y. Lee, C. Yang, J. Wang, J. Brennan, K. H. MacLean, J. Han, T. Chittenden, J. N. Ihle, P. J. McKinnon, J. L. Cleveland, and G. P. Zambetti. 2003. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 4:321–328.
   PubMed Web of Science ®Google Scholar
• Jones, P. A., and S. B. Baylin. 2002. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3:415–428.
   PubMed Web of Science ®Google Scholar
• Kantarjian, H., J. P. Issa, C. S. Rosenfeld, J. M. Bennett, M. Albitar, J. DiPersio, V. Klimek, J. Slack, C. de Castro, F. Ravandi, R. Helmer III, L. Shen, S. D. Nimer, R. Leavitt, A. Raza, and H. Saba. 2006. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106:1794–1803.
   PubMed Web of Science ®Google Scholar
• Kim, H., M. Rafiuddin-Shah, H. C. Tu, J. R. Jeffers, G. P. Zambetti, J. J. Hsieh, and E. H. Cheng. 2006. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat. Cell Biol. 8:1348–1358.
   PubMed Web of Science ®Google Scholar
• Lindström, M. S., U. Klangby, and K. G. Wiman. 2001. p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53. Oncogene 20:2171–2177.
   PubMed Web of Science ®Google Scholar
• Liu, G., J. M. Parant, G. Lang, P. Chau, A. Chavez-Reyes, A. K. El-Naggar, A. Multani, S. Chang, and G. Lozano. 2004. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat. Genet. 36:63–68.
   PubMed Web of Science ®Google Scholar
• Lyko, F., and R. Brown. 2005. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J. Natl. Cancer Inst. 97:1498–1506.
   PubMed Web of Science ®Google Scholar
• Maclean, K. H., U. B. Keller, C. Rodriguez-Galindo, J. A. Nilsson, and J. L. Cleveland. 2003. c-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL. Mol. Cell. Biol. 23:7256–7270.
   PubMed Web of Science ®Google Scholar
• Malumbres, M., I. Perez de Castro, J. Santos, J. Fernandez Piqueras, and A. Pellicer. 1999. Hypermethylation of the cell cycle inhibitor p15INK4b 3′-untranslated region interferes with its transcriptional regulation in primary lymphomas. Oncogene 18:385–396.
   PubMedGoogle Scholar
• Miyashita, T., and J. C. Reed. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293–299.
   PubMed Web of Science ®Google Scholar
• Nakano, K., and K. H. Vousden. 2001. PUMA, a novel pro-apoptotic gene, is induced by p53. Mol. Cell 7:683–694.
   PubMed Web of Science ®Google Scholar
• Nilsson, J. A., U. B. Keller, T. A. Baudino, C. Yang, S. Norton, J. A. Old, L. M. Nilsson, G. Neale, D. L. Kramer, C. W. Porter, and J. L. Cleveland. 2005. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell 7:433–444.
   PubMedGoogle Scholar
• Oda, E., R. Ohki, H. Murasawa, J. Nemoto, T. Shibue, T. Yamashita, T. Tokino, T. Taniguchi, and N. Tanaka. 2000. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288:1053–1058.
   PubMed Web of Science ®Google Scholar
• Peng, H., A. Aiello, G. Packham, P. G. Isaacson, and L. Pan. 1998. Infrequent bax gene mutations in B-cell lymphomas. J. Pathol. 186:378–382.
   PubMedGoogle Scholar
• Ruf, I. K., P. W. Rhyne, H. Yang, C. M. Borza, L. M. Hutt-Fletcher, J. L. Cleveland, and J. T. Sample. 1999. Epstein-Barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma. Mol. Cell. Biol. 19:1651–1660.
   PubMedGoogle Scholar
• Ryan, K. M., and K. H. Vousden. 1998. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol. Cell. Biol. 18:3692–3698.
   PubMed Web of Science ®Google Scholar
• Santos-Rosa, H., and C. Caldas. 2005. Chromatin modifier enzymes, the histone code and cancer. Eur. J. Cancer. 41:2381–2402.
   PubMed Web of Science ®Google Scholar
• Schmitt, C. A., M. E. McCurrach, E. de Stanchina, R. R. Wallace-Brodeur, and S. W. Lowe. 1999. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13:2670–2677.
   PubMed Web of Science ®Google Scholar
• Schmitt, C. A., J. S. Fridman, M. Yang, E. Baranov, R. M. Hoffman, and S. W. Lowe. 2002. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1:289–298.
   PubMed Web of Science ®Google Scholar
• Strasser, A., A. W. Harris, M. L. Bath, and S. Cory. 1990. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348:331–333.
   PubMed Web of Science ®Google Scholar
• Ventura, A., D. G. Kirsch, M. E. McLaughlin, D. A. Tuveson, J. Grimm, L. Lintault, J. Newman, E. E. Reczek, R. Weissleder, and T. Jacks. 2007. Restoration of p53 function leads to tumour regression in vivo. Nature 445:661–665.
   PubMed Web of Science ®Google Scholar
• Villunger, A., E. M. Michalak, L. Coultas, F. Mullauer, G. Bock, M. J. Ausserlechner, J. M. Adams, and A. Strasser. 2003. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302:1036–1038.
   PubMed Web of Science ®Google Scholar
• Vogelstein, B., D. Lane, and A. J. Levine. 2000. Surfing the p53 network. Nature 408:307–310.
   PubMed Web of Science ®Google Scholar
• Wagner, A. J., J. M. Kokontis, and N. Hay. 1994. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. Genes Dev. 8:2817–2830.
   PubMed Web of Science ®Google Scholar
• Wilda, M., J. Bruch, L. Harder, D. Rawer, A. Reiter, A. Borkhardt, and W. Woessmann. 2004. Inactivation of the ARF-MDM-2-p53 pathway in sporadic Burkitt lymphoma in children. Leukemia 18:584–588.
   PubMed Web of Science ®Google Scholar
• Willis, S. N., J. I. Fletcher, T. Kaufmann, M. F. van Delft, L. Chen, P. E. Czabotar, H. Ierino, E. F. Lee, W. D. Fairlie, P. Bouillet, A. Strasser, R. M. Kluck, J. M. Adams, and D. C. Huang. 2007. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315:856–859.
   PubMed Web of Science ®Google Scholar
• Xue, W., L. Zender, C. Miething, R. A. Dickins, E. Hernando, V. Krizhanovsky, C. Cordon-Cardo, and S. W. Lowe. 2007. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445:656–660.
   PubMed Web of Science ®Google Scholar
• Yu, J., L. Zhang, P. M. Hwang, K. W. Kinzler, and B. Vogelstein. 2001. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell 7:673–682.
   PubMed Web of Science ®Google Scholar
• Zindy, F., C. M. Eischen, D. H. Randle, T. Kamijo, J. L. Cleveland, C. J. Sherr, and M. F. Roussel. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12:2424–2433.
   PubMed Web of Science ®Google Scholar